196 related articles for article (PubMed ID: 37386026)
1. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.
Zeng Y; Ma G; Cai F; Wang P; Liang H; Zhang R; Deng J; Liu Y
Cell Death Dis; 2023 Jun; 14(6):386. PubMed ID: 37386026
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
[No Abstract] [Full Text] [Related]
3. SMYD3 regulates the abnormal proliferation of non-small-cell lung cancer cells via the H3K4me3/ANO1 axis.
Zhong D; Zhan Z; Zhang J; Liu Y; He Z
J Biosci; 2022; 47():. PubMed ID: 36222132
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
5. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
6. Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.
Liu H; Liu Y; Kong F; Xin W; Li X; Liang H; Jia Y
J Am Coll Surg; 2015 Aug; 221(2):579-90. PubMed ID: 26077602
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
8. SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells.
Yang Y; Qiu R; Zhao S; Shen L; Tang B; Weng Q; Xu Z; Zheng L; Chen W; Shu G; Wang Y; Zhao Z; Chen M; Ji J
BMC Biol; 2022 Dec; 20(1):294. PubMed ID: 36575438
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Liu Y; Deng J; Luo X; Pan Y; Zhang L; Zhang R; Liang H
Med Oncol; 2015 Jan; 32(1):404. PubMed ID: 25471787
[TBL] [Abstract][Full Text] [Related]
10. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
12. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
13. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Wang Y; Xie BH; Lin WH; Huang YH; Ni JY; Hu J; Cui W; Zhou J; Shen L; Xu LF; Lian F; Li HP
Oncogene; 2019 Jun; 38(25):4948-4961. PubMed ID: 30842588
[TBL] [Abstract][Full Text] [Related]
14. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
15. Smyd3-associated regulatory pathways in cancer.
Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
[TBL] [Abstract][Full Text] [Related]
16. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Dong SW; Zhang H; Wang BL; Sun P; Wang YG; Zhang P
Oncol Rep; 2014 Sep; 32(3):1064-70. PubMed ID: 24993551
[TBL] [Abstract][Full Text] [Related]
17. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Kim JM; Kim K; Schmidt T; Punj V; Tucker H; Rice JC; Ulmer TS; An W
Nucleic Acids Res; 2015 Oct; 43(18):8868-83. PubMed ID: 26350217
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.
Wang P; Zhao L; Rui Y; Ding Y
Cancer Gene Ther; 2023 Apr; 30(4):575-581. PubMed ID: 36127410
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Zhu CL; Huang Q
Dig Dis Sci; 2020 Feb; 65(2):489-499. PubMed ID: 31441002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
